Quantcast

Latest AVI Biopharma Inc. Stories

2010-05-20 11:00:00

VANCOUVER, May 20 /PRNewswire-Asia/ -- Today Insiderslab.com issues new research reports on Down by Half Purchases by company insiders such as CEOs, Presidents, Directors, and 10% shareholders. Insideslab.com tracks large insider purchases when companies are trading at 50% or less of their 52-week high. Today's reports focus on BigBand Networks, Visteon Corp. and AVI Biopharma. Interested parties can learn more about Insiderslab.com and subscribe to FREE insider trading alert newsletters...

2009-10-20 09:28:53

New publication in Molecular Therapy outlines dramatic effects in animals treated with splice switching PPMO, demonstrates promise for treatment of Duchenne muscular dystrophy An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. These findings were published online today in the journal Molecular Therapy and...

2008-10-14 12:00:32

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the Company -- along with The Foundation to Eradicate Duchenne, the CureDuchenne Foundation, and Prosensa -- will co-host an exon skipping conference for Duchenne muscular dystrophy (DMD) from October 14-17, 2008 at the Banbury Center of Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Invited participants will be drawn from all over the world and from all areas of research, clinical development,...

2008-10-14 09:00:11

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the European Medicines Agency (EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending orphan medicinal product designation for AVI-4658 to treat Duchenne muscular dystrophy (DMD). Additionally, the Company received notification from the Gene Therapy Advisory Committee (GTAC) in the UK granting provisional approval for the Company's planned clinical trial for systemic...

2008-10-01 12:00:31

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present at two upcoming healthcare conferences. The first is the JMP Securities Healthcare Focus Conference, to be held October 6-7, 2008 at Le Parker Meridien Hotel in New York City. Dr. Hudson's presentation is scheduled on October 6 at 4:30 p.m. Eastern time. Slides and the webcast link will be available on the Company's website at www.avibio.com...

2008-09-22 09:00:58

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present an update on the continuing transition of AVI from an antisense pioneer into a leading discoverer and developer of RNA-based drugs. The corporate overview will include an update on AVI's Duchenne muscular dystrophy program (DMD), its biodefense projects (which include significant data from the Company's ongoing Ebola and Marburg virus programs in...

2008-09-08 09:00:52

AVI BioPharma, Inc. (NASDAQ: AVII) announced today that it will host a breakfast meeting for analysts, brokers, investors and the Company's shareholders on Wednesday, September 10, 2008, from 7:30 a.m. to 10:30 a.m. EDT at the Harvard Club of New York City. AVI's senior management team will be joined by Dr. Francesco Muntoni, Professor of Pediatric Neurology, University College London Institute of Child Health, and Ben Johnson, Engineering Manager at Global Therapeutics, a Cook Medical...

2008-08-11 09:01:40

AVI BioPharma, Inc. (NASDAQ: AVII) today reported financial results for the three and six months ending June 30, 2008. The Company also reported that it has received approval from the Medicine and Healthcare Product Regulatory Agency (MHRA) to conduct its systemic trial of AVI-4658 in the treatment of Duchenne Muscular Dystrophy in the United Kingdom and also updated the new additions to its senior management team. "As we continue AVI's transformation from an antisense pioneer into an...

2008-08-07 09:01:05

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the Company will hold a conference call to report its second quarter 2008 financial results on Monday, August 11, 2008, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). Individuals interested in listening to the live conference call may do so by dialing 877.704.5378 toll free within the United States and Canada, or 913.312.1268 for international callers. Following the conference call, a recording...

2008-08-04 09:01:05

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, CEO, will present an update on the transitioning of AVI from an antisense pioneer into an RNA-based drug discovery and development company. The corporate overview will include an update on AVI's clinical trials in Duchenne muscular dystrophy, its biodefense projects -- which include significant data from our ongoing Ebola and Marburg virus programs -- its partnership with Cook Medical...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related